Quest Diagnostics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Quest Diagnostics wird ein jährliches Gewinn- und Umsatzwachstum von 9.5% bzw. 2.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 8.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.1% betragen.

Wichtige Informationen

9.5%

Wachstumsrate der Gewinne

8.8%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	2.7%
Zukünftige Eigenkapitalrendite	15.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	11 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts

Apr 26

Recent updates

Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns

May 14

Quest Diagnostics: Let's Keep Waiting

May 08

Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts

Apr 26

We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt

Apr 23

Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares

Apr 02

Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year

Mar 15

Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75

Feb 06

Quest Diagnostics: Post-COVID Normalization Pretty Much Done

Feb 05

Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly

Jan 11

Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price

Dec 24

Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues

Aug 15

Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward

Aug 13

Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate

Jul 11

Is Quest Diagnostics (NYSE:DGX) A Risky Investment?

Jun 09

Quest Diagnostics: Healthier Diagnosis

May 30

Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?

May 24

Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward

May 09

An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued

Mar 22

What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?

Feb 19

Why Quest Diagnostics Isn't A 'Buy', My Oh My

Feb 14

Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's

Feb 05

Quest Diagnostics Q4 2022 Earnings Preview

Feb 01

Quest Diagnostics' unit Pack Health to expand Alabama facility

Jan 17

Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly

Jan 17

Returns On Capital Are Showing Encouraging Signs At Quest Diagnostics (NYSE:DGX)

Jan 03

An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 46% Undervalued

Dec 04

Quest Diagnostics declares $0.66 dividend

Nov 14

Is Now The Time To Look At Buying Quest Diagnostics Incorporated (NYSE:DGX)?

Nov 06

Decode Health, Quest to collaborate to improve biomarker discovery for drug discovery

Oct 18

Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly

Oct 06

Gewinn- und Umsatzwachstumsprognosen

NYSE:DGX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	10,101	1,067	1,377	1,712	10
12/31/2025	9,764	970	1,113	1,542	15
12/31/2024	9,446	895	906	1,309	15
3/31/2024	9,287	842	947	1,332	N/A
12/31/2023	9,252	850	864	1,272	N/A
9/30/2023	9,297	759	596	1,079	N/A
6/30/2023	9,488	790	878	1,374	N/A
3/31/2023	9,603	789	864	1,332	N/A
12/31/2022	9,883	942	1,314	1,718	N/A
9/30/2022	10,294	1,230	1,464	1,865	N/A
6/30/2022	10,582	1,479	1,552	1,924	N/A
3/31/2022	10,679	1,874	1,602	1,982	N/A
12/31/2021	10,788	1,988	1,830	2,233	N/A
9/30/2021	11,046	2,175	1,872	2,293	N/A
6/30/2021	11,058	2,238	2,171	2,594	N/A
3/31/2021	10,335	1,794	2,068	2,489	N/A
12/31/2020	9,437	1,425	1,587	2,005	N/A
9/30/2020	8,361	1,101	1,384	1,812	N/A
6/30/2020	7,531	749	816	1,249	N/A
3/31/2020	7,657	771	779	1,215	N/A
12/31/2019	7,726	835	843	1,243	N/A
9/30/2019	7,639	709	811	1,190	N/A
6/30/2019	7,572	707	929	1,293	N/A
3/31/2019	7,538	720	938	1,295	N/A
12/31/2018	7,531	733	817	1,200	N/A
9/30/2018	7,557	860	914	1,228	N/A
6/30/2018	7,524	808	892	1,188	N/A
3/31/2018	7,469	782	876	1,159	N/A
12/31/2017	7,402	769	N/A	1,175	N/A
9/30/2017	7,398	671	N/A	1,156	N/A
6/30/2017	7,427	701	N/A	1,095	N/A
3/31/2017	7,469	702	N/A	1,112	N/A
12/31/2016	7,214	642	N/A	1,116	N/A
9/30/2016	7,503	675	N/A	1,037	N/A
6/30/2016	7,498	825	N/A	948	N/A
3/31/2016	7,517	748	N/A	922	N/A
12/31/2015	7,493	706	N/A	821	N/A
9/30/2015	7,527	703	N/A	852	N/A
6/30/2015	7,551	491	N/A	911	N/A
3/31/2015	7,528	507	N/A	906	N/A
12/31/2014	7,435	549	N/A	944	N/A
9/30/2014	7,308	506	N/A	845	N/A
6/30/2014	7,192	780	N/A	761	N/A
3/31/2014	7,105	799	N/A	689	N/A
12/31/2013	7,146	811	N/A	652	N/A
9/30/2013	7,164	809	N/A	822	N/A
6/30/2013	7,198	565	N/A	1,030	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DGXDas prognostizierte Gewinnwachstum (9.5% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: DGXDie Erträge des Unternehmens (9.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: DGXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: DGXDie Einnahmen des Unternehmens (2.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: DGXDie Einnahmen des Unternehmens (2.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DGXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.1%).

Quest Diagnostics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year 2023

Quest Diagnostics Incorporated Revises Earnings Guidance for the Full Year 2023

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2023

Recent updates

Quest Diagnostics Incorporated to Report Q2, 2024 Results on Jul 23, 2024

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select assets of PathAI Diagnostics.

First quarter dividend of US$0.75 announced

Quest Diagnostics Elects Robert B. Carte to Board of Directors

Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on July 22, 2024

Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns

Quest Diagnostics: Let's Keep Waiting

Quest Diagnostics Appoints Murali Balakumar as Senior Vice President and Chief Information and Digital Officer

Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt

Quest Diagnostics Incorporated, Annual General Meeting, May 16, 2024

Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares

Upcoming dividend of US$0.75 per share

Quest Diagnostics Incorporated to Report Q1, 2024 Results on Apr 23, 2024

Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year

Insider notifies of intention to sell stock

Quest Diagnostics Incorporated Announces the Launch of MelaNodal Predict

Quest Diagnostics Incorporated Announces the Availability of the First Consumer-Initiated, Physician-Ordered Blood-Draw Test for PFAS Chemicals

Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75

Quest Diagnostics: Post-COVID Normalization Pretty Much Done

Dividend of US$0.75 announced

Full year 2023 earnings: EPS misses analyst expectations

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated to Report Q4, 2023 Results on Feb 01, 2024

Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly

Upcoming dividend of US$0.71 per share at 2.0% yield

Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price

Quest Diagnostics, Inc. Appoints Yuri A. Fesko, M.D. as Senior Vice President and Chief Medical Officer

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel

Quest Diagnostics: Market Overreaction Creates Investment Opportunity

Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?

Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on January 31, 2024

Quest Diagnostics Launches Mobile Phlebotomy Service, Enabling Convenient At-Home Specimen Collection in the United States

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year 2023

Quest Diagnostics: Moving Past Covid

Quest Diagnostics Incorporated to Report Q3, 2023 Results on Oct 24, 2023

Upcoming dividend of US$0.71 per share at 2.3% yield

Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly

What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?

Quest Diagnostics Grants Fda Breakthrough Designation for Its Adeno-Associated Virus Test

Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on October 23, 2023

Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues

Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward

QuQuest Diagnostics Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com

Quest Diagnostics Incorporated Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Quest Diagnostics Announces the Launch of its First Consumer-Initiated Genetic Test

Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate

Upcoming dividend of US$0.71 per share at 2.0% yield

Quest Diagnostics Incorporated to Report Q2, 2023 Results on Jul 26, 2023

Is Quest Diagnostics (NYSE:DGX) A Risky Investment?

Quest Diagnostics: Healthier Diagnosis

Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?

Quest Diagnostics Elects Luis A. Diaz to Its Board

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 25, 2023

Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Upcoming dividend of US$0.71 per share at 2.1% yield

An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued

Senior VP & General Counsel notifies of intention to sell stock

Insider notifies of intention to sell stock

Now 21% undervalued after recent price drop

What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?

Quest Diagnostics Incorporated (NYSE:DGX) entered into a definitive agreement to acquire Select Assets of the Laboratory Services Business from The New York and Presbyterian Hospital.